Skip to content
2000
Volume 16, Issue 4
  • ISSN: 1573-4064
  • E-ISSN: 1875-6638

Abstract

Background: Approximately, 5-7 million people are infected with T. cruzi in the world, and approximately 10,000 people per year die of complications linked to this disease. Methods: This work describes the construction of a new family of hidrazonoyl substituted derivatives, structurally designed exploring the molecular hybridization between megazol and nitrofurazone. Results and Discussion: The compounds were evaluated for their in vitro activity against bloodstream trypomastigotes of Trypanosoma cruzi, etiological agent of Chagas disease, and for their potential toxicity to mammalian cells. Conclusion: Among these hydrazonoyl derivatives, we identified the derivative (4) that showed trypanocidal activity (IC50/24 h = 15.0 μM) similar to Bz, the standard drug, and low toxicity to mammalian cells, reaching an SI value of 18.7.

Loading

Article metrics loading...

/content/journals/mc/10.2174/1573406415666190712115237
2020-06-01
2025-05-24
Loading full text...

Full text loading...

/content/journals/mc/10.2174/1573406415666190712115237
Loading

  • Article Type:
    Research Article
Keyword(s): Chagas' disease; chemotherapy; Hydrazonoyl; megazol; nitrofurazone; Trypanosoma cruzi
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test